TNFRSF14 is a potential suitable target for developing new ICB strategies in malignant glioma, and the combination of TNFRSF14 blockade with anti-PD-L1 provides synergic benefit for GBM. This evidence concerns the gene TNFRSF14 and malignant glioma.